Saskatoon Berry on Metabolism and Gut Microbiota in Healthy Subjects
Primary Purpose
Nutritional and Metabolic Diseases
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Saskatoon berry
Sponsored by
About this trial
This is an interventional treatment trial for Nutritional and Metabolic Diseases focused on measuring Saskatoon berry, Glucose tolerance, Gut microbiota, Healthy subjects
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects living in Winnipeg.
- Willingness to sign an informed consent.
Exclusion Criteria:
1. History of myocardial infarction, stroke, hypertension, diabetes, hyperlipidemia, chronic kidney disease.
2) Participants are taking hypoglycemic, anti-hypertensives, lipid lowering medications or antibiotics within a 1 month.
Sites / Locations
- University of ManitobaRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single arm
Arm Description
Single arm
Outcomes
Primary Outcome Measures
Glucose tolerance
75 g oral glucose tolerance test (2 h postprandial plasma glucose in mM/L)
Gut microbiome
Stool will be collected for 16S rRNA gene sequencing in % of abundance
Secondary Outcome Measures
Lipid profile
total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol in mM/L
C-reactive protein
C-reactive protein in mg/L
Liver enzymes
ALT, AST in units/L
Body mass index accord to body weight and height
Body weight in kg, heights in cm, and body mass index in kg/M^2
Blood pressure
Systolic and diastolic blood pressure in mmHg
Tumor necrosis factor-alpha
Tumor necrosis factor-alpha in pg/mL
Full Information
NCT ID
NCT04809688
First Posted
October 15, 2020
Last Updated
May 10, 2023
Sponsor
University of Manitoba
Collaborators
Diabetes Canada
1. Study Identification
Unique Protocol Identification Number
NCT04809688
Brief Title
Saskatoon Berry on Metabolism and Gut Microbiota in Healthy Subjects
Official Title
Pilot Study on the Effects of Saskatoon Berry on Glucose Metabolism, Insulin Resistance and Gut Microbiota in Healthy Human Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 8, 2023 (Actual)
Primary Completion Date
December 20, 2023 (Anticipated)
Study Completion Date
December 20, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Manitoba
Collaborators
Diabetes Canada
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Diabetes becomes epidemic in worldwide countries. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Our recent studies demonstrated Saskatoon berry powder (SBp) attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The results in antidiabetic activities of SBp have been supported by other groups in high fat fed rats. The combination of findings suggest that Saskatoon berry is good candidate of prebiotic functional food as a supplemental remedy for reducing insulin resistance, metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in human subjects. We propose to examine the effect of oral administration of freeze-dried Saskatoon berry on glucose metabolism, insulin resistance and gut microbiota in healthy adults in a pilot trial.
Detailed Description
Subject recruitment: Healthy subjects (males and females, 18-75 years of age) in Winnipeg, who are voluntarily signing an informed consent approved by Research Ethics Board in University of Manitoba, will be eligible to the study. Exclusion criteria include: 1) candidates have a history of myocardial infarction, stroke, hypertension, diabetes, hyperlipidemia, chronic kidney disease; 2) participants are taking hypoglycemic, anti-hypertensives, lipid lowering medications or antibiotics within a month.
Dietary product: Freeze dried Saskatoon berry have been obtained from Prairie Berries Inc. The berries were freshly frozen and no any supplementation was added to the dried berry. The product has been processed by certified facilities and the batch of dried berry has passed pathogen analysis.
Regimen: Participants (n=20) will orally administrate 30 g/day of freeze dried Saskatoon berry during breakfast for 10 weeks.
Scheduled visits:
Visit 1: Consent and enrollment. A questionnaire for domestic questionnaire including dietary intake and physical activity will be filled. Measurements of body weight, height and blood pressure will be taken during the visit.
Visit 2 (<1 week from the visit 1 and before the start of berry administration): 75 g oral glucose tolerance test (OGTT) after an overnight fasting. Insulin, liver enzymes (alanine transaminase or ALT, aspartate transaminase or AST), creatinine, lipid profile and inflammation markers (e. x. tumor necrosis factor-alpha or TNF-alpha) will be measured as baseline.
Participants will be provided with sealed packages of dried Saskatoon berry and instruction of the administration. Insulin and lipid profile will be tested in blood samples withdrawn at fast glucose for OGTT.
Visit 3 (at 5 weeks after the start of administration of Saskatoon berry): Participants will be asked to provide feedback on general well-being and the intake of Saskatoon berry. Body weight, blood pressure and heart rate will be measured and recorded.
Visit 4 (at 10 weeks after the start of the dietary regimen): Participants will be asked to collect stool sample with the collection kit within 1 week before the visit and bring it to the visit. They will also be asked to have an overnight fasting the night before visit. They will receive an OGTT. Blood samples for insulin, liver enzymes, creatinine, lipid profile and inflammation markers will be collected from each participant. During the visit, body weight, blood pressure and heart rate of participants will be taken. Questionnaires on participants' dietary intake, physical activity and feedback to the study will be completed.
Participants will receive a $50 honorarium gift card for their participation. Sample collection and analyses: OGTT, ALT, AST, creatinine and lipid profile will be analyzed in Clinical Chemistry in Health Science Centre, Winnipeg. Inflammation mediators will be analyzed in the Dr. G. Shen's laboratory. Homeostatic model assessment-insulin resistance or homeostatic model assessment for insulin resistance (HOMA-IR) will be calculated based on fasting plasma glucose and insulin. Stool samples will be aliquoted and stored under -80°C before submission. Microbiome analysis will be conducted in Integrate Microbiome Resource at Dalhousie University.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nutritional and Metabolic Diseases
Keywords
Saskatoon berry, Glucose tolerance, Gut microbiota, Healthy subjects
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Healthy subject (n=20) will be enrolled in a single group for oral administration of dried Saskatoon berry as snack.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Single arm
Arm Type
Experimental
Arm Description
Single arm
Intervention Type
Dietary Supplement
Intervention Name(s)
Saskatoon berry
Intervention Description
Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
Primary Outcome Measure Information:
Title
Glucose tolerance
Description
75 g oral glucose tolerance test (2 h postprandial plasma glucose in mM/L)
Time Frame
Changes from baseline to 10 weeks after the start of dietary intervention
Title
Gut microbiome
Description
Stool will be collected for 16S rRNA gene sequencing in % of abundance
Time Frame
Changes from baseline to 10 weeks after the start of dietary intervention
Secondary Outcome Measure Information:
Title
Lipid profile
Description
total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol in mM/L
Time Frame
Onset and 10 weeks after the start of dietary intervention
Title
C-reactive protein
Description
C-reactive protein in mg/L
Time Frame
Onset and 10 weeks after the start of dietary intervention
Title
Liver enzymes
Description
ALT, AST in units/L
Time Frame
Onset and 10 weeks after the start of dietary intervention
Title
Body mass index accord to body weight and height
Description
Body weight in kg, heights in cm, and body mass index in kg/M^2
Time Frame
Onset, 5 and 10 weeks after the start of dietary intervention
Title
Blood pressure
Description
Systolic and diastolic blood pressure in mmHg
Time Frame
Onset, 5 and 10 weeks after the start of dietary intervention
Title
Tumor necrosis factor-alpha
Description
Tumor necrosis factor-alpha in pg/mL
Time Frame
Onset, 5 and 10 weeks after the start of dietary intervention
Other Pre-specified Outcome Measures:
Title
Dietary intake, physical activities
Description
3 day food intake and the type in gram, frequency in time/day and length of physical activities index in artificial score (score scale 0-3, high means more activity)
Time Frame
Onset and 10 weeks after the start of dietary intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy subjects living in Winnipeg.
Willingness to sign an informed consent.
Exclusion Criteria:
1. History of myocardial infarction, stroke, hypertension, diabetes, hyperlipidemia, chronic kidney disease.
2) Participants are taking hypoglycemic, anti-hypertensives, lipid lowering medications or antibiotics within a 1 month.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Garry Shen, MD PhD
Phone
204-789-3816
Email
garry.shen@umanitoba.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Amy Hui, PhD
Phone
204-780-3985
Email
amy.hui@umanitoba.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Garry Shen, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Manitoba
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3E 3P4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Garry Shen, MD PhD
Phone
204-789-3816
Email
gshen@ms.umanitoba.ca
First Name & Middle Initial & Last Name & Degree
Amy Hui, PhD
Phone
204-789-3985
Email
Amy.Hui@umanitoba.ca
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31078906
Citation
Zhao R, Khafipour E, Sepehri S, Huang F, Beta T, Shen GX. Impact of Saskatoon berry powder on insulin resistance and relationship with intestinal microbiota in high fat-high sucrose diet-induced obese mice. J Nutr Biochem. 2019 Jul;69:130-138. doi: 10.1016/j.jnutbio.2019.03.023. Epub 2019 Apr 9.
Results Reference
background
PubMed Identifier
32824001
Citation
Huang F, Zhao R, Xia M, Shen GX. Impact of Cyanidin-3-Glucoside on Gut Microbiota and Relationship with Metabolism and Inflammation in High Fat-High Sucrose Diet-Induced Insulin Resistant Mice. Microorganisms. 2020 Aug 14;8(8):1238. doi: 10.3390/microorganisms8081238.
Results Reference
background
PubMed Identifier
32230955
Citation
du Preez R, Wanyonyi S, Mouatt P, Panchal SK, Brown L. Saskatoon Berry Amelanchier alnifolia Regulates Glucose Metabolism and Improves Cardiovascular and Liver Signs of Diet-Induced Metabolic Syndrome in Rats. Nutrients. 2020 Mar 27;12(4):931. doi: 10.3390/nu12040931.
Results Reference
background
Learn more about this trial
Saskatoon Berry on Metabolism and Gut Microbiota in Healthy Subjects
We'll reach out to this number within 24 hrs